BioNTech Reports €2.8B Revenue, Strategic Oncology Advances for 2024

BioNTech SE reported a significant decrease in revenues for 2024, totaling €2.8 billion, largely due to reduced sales of its COVID-19 vaccines and write-downs from partner Pfizer. The fourth quarter saw revenues decline to €1.19 billion from €1.48 billion the previous year, with earnings per share dropping to $1.08. Despite these financial challenges, BioNTech emphasized progress in its oncology pipeline, including the initiation of global Phase 3 trials for the BNT327 candidate. The company anticipates revenues for 2025 to range between €1.7 billion and €2.2 billion, with expectations of a data-rich year ahead. CEO Prof. Ugur Sahin expressed confidence in the potential of its oncology programs to disrupt current treatment standards. BioNTech's strategic investments aim to bolster R&D and prepare for future product launches.